Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Capital Expenditures for 16 consecutive years, with $648000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 91.49% to $648000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, down 11.74% year-over-year, with the annual reading at $6.8 million for FY2025, 11.74% down from the prior year.
  • Capital Expenditures for Q4 2025 was $648000.0 at Anika Therapeutics, down from $1.9 million in the prior quarter.
  • The five-year high for Capital Expenditures was $7.6 million in Q4 2024, with the low at -$5.1 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $815684.2, with a median of $648000.0 recorded in 2025.
  • The sharpest move saw Capital Expenditures tumbled 14676.47% in 2021, then soared 716.61% in 2023.
  • Over 5 years, Capital Expenditures stood at -$205000.0 in 2021, then tumbled by 179.02% to -$572000.0 in 2022, then plummeted by 384.62% to -$2.8 million in 2023, then surged by 374.75% to $7.6 million in 2024, then crashed by 91.49% to $648000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $648000.0, $1.9 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.